Publication
The somatic affairs of BRAF: tailored therapies for advanced malignant melanoma and orphan non-V600E (V600R-M) mutations.
Authors not recorded
J Clin Pathol2013PMID 23463675stubpubmedProvenance
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
No abstract stored. Read on PubMed
Linked entities
Linked entities (4)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 4
- cancerMelanomacivic_curation1.00
- drugDabrafenibcivic_curation1.00
- geneBRAFcivic_curation1.00
- variantBRAF V600Dcivic_curation1.00
Curated evidence
Evidence citing this paper (2)
civicProvenance
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 23463675
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| DBI PROMOTER DEMETHYLATION1 | ||||||||
| (diagnostic) | Lymphoma | Diagnostic | B | Supports Positive | 5 | rejected | civic | |
| BRAF V600D1 | ||||||||
| Dabrafenib | Melanoma | Predictive | B | Supports Sensitivity Response | 5 | accepted | EID94Patients with other BRAF V600 mutations also respond well to the V600E drug dabrafenib. PMID 23463675 · Ponti et al., 2013 · Open in CIViC | civic |